Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148520 | 0.94 | MEN1 (0.32) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL1149044 | 0.92 | MEN1 (0.31) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL16401965 | 0.92 | MEN1 (0.31) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL4334790 | 0.92 | MEN1 (0.31) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL24101 | 0.86 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL31079997 | 0.85 | CHRNB2 (0.37) | LMNA | |
| SCHEMBL15569600 | 0.84 | MEN1 (0.33) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL19025042 | 0.80 | FOLH1 (0.36) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL790160 | 0.80 | MEN1 (0.33) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL10830752 | 0.80 | CA12 (0.40) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503463-B2 | Aliphatic acid amide derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-12-23 | — | — | US | disclosed |
| EP-4082616-B1 | ALIPHATIC ACID AMIDE DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| WO-2025082069-A1 | COMPOUND BINDING TO CRBN PROTEIN AND DEGRADATION AGENT OF PROTEIN | 中国海洋大学 | 2025-04-24 | — | — | WO | disclosed |
| US-20250066287-A1 | PHASE CHANGE AROMATIC AZO COMPOUNDS, METHOD OF MANUFACTURE, AND USE AS HOMOGENOUS CATALYST | BRANDEIS UNIVERSITY | 2025-02-27 | — | — | US | disclosed |
| WO-2025036132-A1 | COMPOUND AND USE THEREOF | 中国海洋大学 | 2025-02-20 | — | — | WO | disclosed |
| US-20240360149-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2022-12-08 | — | — | US | disclosed |
| EP-4082616-A1 | ALIPHATIC ACID AMIDE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-11472891-B2 | Photocrosslinkable alginic acid derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-18 | — | — | US | disclosed |
| US-20110183960-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2343291-A1 | 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg-Universität Mainz (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2338486-A1 | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz (DE) | 2011-06-29 | — | — | EP | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| US-7928225-B2 | Oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2011-04-19 | — | — | US | disclosed |
| US-7884114-B2 | N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide for treatment of allergic rhinitis | GLAXO GROUP LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| US-20100184770-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-07-22 | — | — | US | disclosed |
| EP-2091538-B1 | 4-BENZYL-1(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-03-03 | — | — | EP | disclosed |
| WO-2004012506-A2 | ANTIMICROBIAL COMPOUNDS | EXEGENICS, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066287-A1 | PHASE CHANGE AROMATIC AZO COMPOUNDS, METHOD OF MANUFACTURE, AND USE AS HOMOGENOUS CATALYST | CTSV, CTSS, CMA1 | MEN1 1745/4885KMT2A 2419/4885HTT 1935/4885 |
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | TARDBP, TDP1, TDP2 | MEN1 4845/4885KMT2A 3379/4885HTT 7/4885 |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | MEN1 1922/4885KMT2A 891/4885HTT 954/4885 |
| US-20100184770-A1 | COMPOUNDS | CMA1, TSLP, IL5 | MEN1 318/4885KMT2A 3409/4885HTT 1450/4885 |
| US-20110183960-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NR3C2, NR1H3, NR1H2 | MEN1 4467/4885KMT2A 2317/4885HTT 2839/4885 |
| US-12503463-B2 | Aliphatic acid amide derivative | HTR2A, HTR1A, HTR7 | MEN1 2014/4885KMT2A 332/4885HTT 1450/4885 |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GABRA5, SLC6A11, GABRA1 | MEN1 2159/4885KMT2A 4330/4885HTT 4271/4885 |
| US-20240360149-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | MEN1 41/4885KMT2A 2349/4885HTT 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.